The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: TNF-alpha inhibitors (Amgen \/ Pfizer\u2019s Enbrel, AbbVie\u2019s Humira, Johnson & Johnson Innovative Medicine\u2019s Remicade and Simponi \/ Simponi Aria, and UCB\u2019s Cimzia) and IL-17 inhibitors (Novartis\u2019s Cosentyx and Eli Lilly\u2019s Taltz). TNF-alpha inhibitors are the most prescribed biologics for AxSpA that is refractory to NSAIDs, but branded TNF-alpha inhibitors face competition from the cost-effective biosimilars and the growing IL-17 class. In 2019, the FDA approved Cimzia for nonradiographic (nr)-AxSpA, the first FDA approval for this subpopulation, followed by both IL-17 inhibitors in June 2020 and AbbVie\u2019s Rinvoq in October 2022. The approval of novel oral targeted therapies\u2014JAK inhibitors (Rinvoq and Pfizer\u2019s Xeljanz)\u2014for ankylosing spondylitis and the recent approval of an additional IL-17 inhibitor (UCB\u2019s Bimzelx) for AxSpA will only heighten the competition and further reshape the treatment of this disease.<\/p>\n
Questions answered:<\/strong><\/p>\n Content highlights:<\/strong><\/p>\n Geographies: United States, EU5, Japan<\/p>\n Primary research: 34 country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.<\/p>\n Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.<\/p>\n Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n Drug treatments:\u00a0Coverage of key current and late-phase emerging therapies<\/p>\n Product description: <\/strong>Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n